 Provider News KentuckySeptember 1, 2023 September 2023 Provider Newsletter Featured Articles Administrative | Commercial / Medicaid | August 18, 2023 Digital Solutions | Medicaid | September 1, 2023 Administrative | Commercial | September 1, 2023 Products & Programs | Medicare Advantage | September 1, 2023
KYBCBS-CDCRCM-035541-23 Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. Availity, LLC is an independent company providing administrative support services on behalf of the health plan. During the COVID-19 public health emergency, Medicaid, and Children’s Health Insurance Program (CHIP) members were able to stay enrolled in their current health coverage regardless of changes in eligibility or status. As Medicaid renewals begin again, your Medicaid and CHIP patients may have to take additional steps, which could include finding a new health plan. Patients who are receiving specialized care for medical conditions such as but not limited to pregnancy, chemotherapy, radiation therapy, or behavioral health therapy may have additional concerns. They could be in the middle of treatment, scheduled for treatment, or on maintenance medications — and may be worried that they might lose access to their current care provider if they change health plans. The need for continuity of care in this changing landscapeWe’re committed to ensuring a smooth transition for your Medicaid and CHIP patients who are changing health plans. Our Continuity of Care/Transition of Care management team coordinates with you and your patients to ensure access to ongoing care. This includes a personalized evaluation of the member’s condition and network benefits to coordinate and minimize disruption of ongoing care: - Your patients can contact the number on the back of their member ID card and ask about our Transition of Care form. Once filled out, one of our dedicated nurse care managers will contact them to review their specialized care needs within 15 business days.
- Download our Commercial provider manual to learn more about our Continuity of Care/Transition of Care Program. Refer to the table of contents and find Continuity of Care/Transition of Care Program under the Quality Improvement Program section.
A proactive approach to prior authorizationsFor patients with CarelonRx, Inc.* as their pharmacy benefit manager and who are on maintenance medications or other medications for treatment, their existing, approved prior authorizations will automatically transfer to their new Anthem individual and family health plan, and there will be a one-time prior authorization applied for nonformulary medications. This will allow your patients to continue to fill their current medications and allow additional time to initiate the prior authorization process for any formulary differences. You and your patients can count on us for supportYour patients who are receiving specialized care may have concerns about continuing their care and staying with their current care providers. We want you to feel confident you have resources and answers to guide them. Together, we can ease your patients’ potential concerns and ensure a smooth transition for those who choose an Anthem individual and family health plan. If you would like more information, contact your Provider Relationship Management representative or call the number on the back of the patient’s ID card. * CarelonRx, Inc. is an independent company providing pharmacy benefit management services on behalf of the health plan. KYBCBS-CDCM-026684-23-CPN26000 We ask that you review your online provider directory information on a regular basis to ensure it is correct. Access your information by visiting anthem.com/provider, then under Provider Overview, choose Find Care. The Consolidated Appropriations Act (CAA) of 2021 contains a provision that requires online provider directory information be reviewed and updated as needed at least every 90 days. By reviewing your information regularly, you help us ensure your online provider directory information is current. Submit updates and corrections to your directory information by following the instructions on our Provider Maintenance webpage. We will send you an email acknowledging receipt of your request. Online update options include: - Add/change an address location.
- Name change.
- Provider leaving a group or a single location.
- Phone/fax number changes.
- Closing a practice location.
MULTI-BCBS-CM-034855-23-CPN34821 As part of our ongoing quality improvement efforts, we want you to know that some review requests may require documentation to substantiate the attestations that support the clinical appropriateness of the request. This documentation can be uploaded during the intake process. When requested, providers must submit such documentation from the patient’s medical record. If medical necessity is not supported through documents submitted, the request may be denied as not medically necessary. Such documentation is limited to what has been asserted via the prior authorization (PA) review attestations. If the request would be denied as not medically necessary, providers can participate in a PA discussion with an Carelon Medical Benefits Management physician reviewer. * Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. MULTI-BCBS-CM-034178-23-CPN34175 In the April 2023 edition of Provider News, it was announced that for claims processed on and after May 15, 2023, we would update our claims editing process for outpatient facility claims by applying the outpatient code editor National Correct Coding Initiative (NCCI). This update was delayed and as a result, the NCCI edits will be applied to claims processed on and after October 1, 2023. As a reminder, NCCI edits are Centers for Medicaid & Medicare Services (CMS) developed guidelines to promote national correct coding based on industry standards for current coding practices. These edits provide an opportunity to shift certain existing back-end reviews to front-end adjudication for outpatient facility claims. While this may facilitate quicker claim adjudication, it may also cause claims to be denied if correct coding guidelines are not followed. This includes, but is not limited to, scenarios with procedure-to-procedure editing (for example, mutually exclusive or the procedure is a component of another procedure). For additional information, visit CMS.gov. If you have questions about this communication or need assistance with any other item, contact your Provider Relationship Management representative. The American Cancer Society (ACS) recommends annual fecal immunochemical test (FIT) kit testing for all adults aged 45 and older with average risk for colon cancer. For these patients, the FIT kit is a convenient, cost-effective, and discreet testing option.1, 2 FIT kits offer a cost-effective, highly accurate option for colorectal cancer screening Screening with FIT kits is convenient and easier than ever. Adopting FIT screening into your practice can help increase patient adherence to colon cancer screening recommendations. Annual FIT improves screening rates and has also been shown to save lives.3 Anthem Blue Cross and Blue Shield network physicians and their patients have access to high-quality, low-cost colorectal cancer screening FIT kits through our National Lab partners Labcorp and Quest Diagnostics.* If you have specific questions, please contact the labs directly: To find Labcorp, Quest Diagnostics, and other participating labs in your patient’s plan network, select Find Care from the Provider Resources menu at anthem.com. References: 1. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society.CA Cancer J Clin.2018;68(4):250-281. 2. Occult blood, fecal, immunoassay. Laboratory Corporation of America Holdings and Lexi-Comp Inc. 2021. Accessed April 11, 2022. https://bit.ly/3pRHPlV. 3. Dougherty MK, Brenner AT, Crockett SD, et al. Evaluation of interventions intended to increase colorectal cancer screening rates in the United States: a systematic review and meta-analysis. JAMA Intern Med. 2018;178(12):1645-1658.
* Quest Diagnostics is an independent company providing preventive care technology and health risk assessments services on behalf of the health plan. MULTI-BCBS-CM-024720-23-CPN24527, MULTI-BCBS-CM-034185-23 Effective for all claims received on and after October 1, 2023, Anthem Blue Cross and Blue Shield (Anthem) is updating its outpatient facility editing system to align with correct coding guidelines. For claims received on or after October 1, 2023, when revenue codes 0278, 0636, 0760, 0761, 0762, and 0769 are billed with an inappropriate HCPCS or CPT® code, they will be denied. For assistance with coding guidelines, please refer to CPT coding guidelines and Encoder Pro. If you believe you have received a denial in error, please follow the standard claim dispute process for Anthem. Starting mid-September, search for patient information in Availity Essentials* Eligibility and Benefits without having a member ID. We’ve updated and streamlined the process to eliminate the need for the member ID while maintaining the highest HIPAA standards. Easily search for patient eligibility and benefits details using the Patient Search option of patient last name, patient first name, date of birth, and patient zip code. Find Eligibility and Benefits Inquiry on Availity’s top menu bar under Patient Registration. Once it becomes available, make sure to use the new search feature when you need to find member information and do not have access to the member ID. Need the member ID for another capability in Availity Essentials? When you use the new search option in Eligibility and Benefits Inquiry and see the eligibility and benefits details, the member’s current ID details will be available and allow you to transact within other digital capabilities where the member ID is required. Watch for more information on the Availity Essentials home page under News and Announcements to notify you when this feature is available. Get access to Availity Essentials nowIf you and your organization aren’t currently registered for Availity Essentials, now is the time to make that happen. Availity Essentials offers secure online access for working together and is free to our providers. To register, visit the availity.com Registration Information page. * Availity, LLC is an independent company providing administrative support services on behalf of the health plan. MULTI-BCBS-CM-025687-23-CPN25562 Digital Request for Additional Information (Digital RFAI) is the fastest and easiest way to get us the documents we need to process your claim. Now, it is even better! We’ve added filter, sort, and search features for greater productivity. New filtering functions are ideal for organizations where more than one person is responsible for submitting claim attachments. Another great feature: your filters are saved (locked) – so you can see your desired filter view each time you log on but easily clear them when your search criteria changes.

We are committed to shared success and reporting is just another way we are giving Digital RFAI users a productivity boost. We’ve added reporting fields that can be used for both History and Inbox reports. Fields available for History and Inbox reports
Expanded reporting fields are downloadable! Use the download option to meet your specific reporting requirements. 
We’re here to help! Want to know more about receiving digital notifications for faster claims processing? Visit the Digital RFAI learning microsite or reach out to your Provider Relations Account Manager. MULTI-BCBS-CM-035616-23-CPN35217 Description/Approach Provider performance can vary widely in relation to efficiency and quality. Our goal as your Medicare health plan partner is to ensure our members receive high-quality care that leads to improved member health outcomes across a wide range of variables. We will add a new sorting option on the Find Care tool for members to leverage when they are searching for a non-PCP specialist provider. This sorting option, called Personalized Match Phase 1, is based on each provider’s score relative to their peers in the patient’s preferred mileage search radius. Providers will be listed in order of their total score, though no individual scores will appear within the tool or be visible to the covered patients. The Personalized Match Phase 1 algorithm will be based on quality and efficiency criteria to assist members in making more informed choices about their medical care. Other sorting options will still be available on Find Care for our members. Members should consider a variety of factors when making decisions for choosing a specialist provider to manage their care. We evaluate provider groups and individual providers annually, using updated quality and efficiency methodologies and data. Continue reading the rest of this article * Optum is an independent company providing assessment and reporting services on behalf of the health plan. MULTI-BCBS-CR-032277-23-CPN32264 ATTACHMENTS (available on web): Personalized Match Phase 1: Specialist Provider Overview (pdf - 0.59mb) We understand that providing the information needed to process a claim can cause payment delays, and the manual methods associated with mailing letters and returning information non-digitally is costly and inefficient. We’re changing that by implementing a new process: Digital Request for Additional Information (Digital RFAI), and we’re inviting you to participate. Digital requests for additional information are 50% faster than returning documentation any other way — making it the most efficient way to receive and return information — resulting in faster claim payments. Participation in Digital RFAI is easy- Registration:
- Your organization’s Availity* administrator will register for Medical Attachments:
- This enables you to receive digital notices (instead of paper) and to attach the requested documents directly to your claim.
- Ensure all of your billing NPIs/TINs are registered.
- User roles:
- Your Availity administrator will also update or add new users with these specific role assignments through Availity Essentials:
- Claims Status
- Medical Attachments
- This enables the users to view the Availity Attachment Dashboard.
- Ready to go:
- After the registration and user roles are completed on Availity, the Digital RFAI process is ready to go.
- Requests will automatically appear on the Attachments Dashboard each morning (when documents are needed).
Additional supportYou, your organization’s Availity administrator, or other members of your team may need additional support – and we’re to help: - For Availity Administrators: Take this training to ensure your NPIs are registered properly.
- For those sending attachments: Take this user training to learn about accessing notifications, sorting and filtering, and other enhancements that improve your experience.
Through our efforts, we are committed to reducing administrative burden and ensuring timely payments because we value you, our care provider partner. For additional resources, visit the Digital RFAI webpage or contact your Provider Relations Account Manager. * Availity, LLC is an independent company providing administrative support services on behalf of the health plan. MULTI-BCBS-CM-036134-23-CPN35203 As we communicated in July, we will use the Provider Data Management (PDM) application on Availity Essentials* to verify and initiate care provider demographic change requests for all professional and facility care providers.** Going forward, Availity PDM is now the intake application for care providers to submit demographic change requests, including submitting roster uploads. Availity PDM will replace all current intake channels for demographic change requests and roster submissions as of October 1, 2023. If preferred, providers may continue to utilize the Provider Enrollment application in Availity to submit requests to add new practitioners under existing groups. Take action nowDon’t wait until October to start using the PDM application. Start using it today to take advantage of the benefits of this application and familiarize yourself with the process before the legacy intake channels retire. What features does the Availity PDM application provide?It allows you to: - Update provider demographic information for all assigned payers in one location.
- Attest and manage current provider demographic information.
- Review the history of previously verified data.
Benefits to our care providers using Availity PDMThe Availity PDM application will ensure the following: - Consistently updated data
- Decreased turnaround time for updates
- Compliance with federal and/or state mandates
- Improved data quality through standardization
- Increased provider directory accuracy
- Choice and flexibility to request data updates via the standard PDM experience or by submitting a spreadsheet via a roster upload
Want to submit a roster using Availity PDM?Don’t wait — Start submitting today. Roster Automation is our new technology solution designed to streamline and automate provider data additions, changes, and terminations that are submitted using a standardized Microsoft Excel submission. Any provider, whether an individual provider/practitioner, group, or facility, can use Roster Automation today:*** - Utilize the Roster Automation Standard Template:
- For your convenience, there is a standard roster Excel document. Find it online here.
- Follow the Roster Automation Rules of Engagement:
- A reference document, Roster Automation Rules of Engagement, is available to ensure error-free submissions, driving accurate and more timely updates through automation. More detailed instructions on formatting and submission requirements can also be found on the first tab of the Roster Automation Standard Template (User Reference Guide). Find it online here.
- Upload your completed roster via the Availity PDM application.
- Join our live webinar:
- Title of webinar: Roster Automation Template and Rules of Engagement Training
- Date: Monday, August 21, 2023
- Time: 4 to 5 p.m. ET
- Registration link: here
What about the previous methods by which I have been submitting information?While we are in the process of sunsetting our legacy intake channels, we will continue to process submissions received through current intake channels until September 30, 2023. Effective October 1, 2023, all PDM requests, including rosters, must be submitted via Availity PDM. As of this date, all provider demographic change requests, including rosters, will be rejected if submitted through any format/channel other than Availity PDM. Again, if preferred, providers may continue to utilize the Provider Enrollment application in Availity to submit requests to add new practitioners under existing groups. How to access the Availity PDM applicationLog onto availity.com and select My Providers > Provider Data Management to begin the attestation process. If submitting a roster, find the TIN/business name for which you want to verify and update information. Before you select the TIN/business name, select the three-bar menu option on the right side of the window, and select Upload Rosters (see screen shot below) and follow the prompts. 
Availity administrators will automatically be granted access to PDM. Additional staff may be given access to Provider Data Management by an administrator. To find your administrator, go to My Account Dashboard > My Account > Organization(s) > Administrator Information. Training is available:- Learn about and attend one of our training opportunities by visiting here.
- View the Availity PDM quick start guide here.
Not registered for Availity yet?If you aren’t registered to use Availity Essentials, signing up is easy and 100% secure. There is no cost for your providers to register or to use any of the digital applications. Start by logging into availity.com and selecting the Register icon at the top of the home screen, or you can use this link to access the registration page. If you have questions regarding registration, reach out to Availity Client Services at 800‑AVAILITY. Note: For national providers who provide services in multiple markets, California (all lines of business), Colorado (Commercial and Medicare), and Nevada (all lines of business) are not available for Availity PDM until our Strategic Provider System migration. ** Exclusions: - Behavioral health providers assigned to Carelon Behavioral Health, Inc.* will continue to follow the process for demographic requests and/or roster submissions, as outlined by Carelon Behavioral Health.
- Any specific state mandates or requirements for provider demographic updates.
*** If any roster data updates require credentialing, your submission will be routed appropriately for further action. * Availity, LLC is an independent company providing administrative support services on behalf of the health plan. Carelon Behavioral Health, Inc. is an independent company providing utilization management services on behalf of the health plan. KYBCBS-CD-031770-23-CPN30214 Register today for the youth mental health forum hosted by Anthem and Motivo* for Anthem providers on September 27, 2023. Wednesday, September 27, 2023 3:30 to 5 p.m. Eastern time This important event will address the critical need to engage young people in leading their mental health. By deepening the discussion on youth mental health, we can do our part to foster a culture of understanding and support for youth and young adults. Authentic conversations lead to reducing implicit bias and improving the health and wellbeing of all Americans and the communities in which we live and serve. Please join us to hear from a diverse panel of experienced professionals and young leaders as we explore the challenges experienced by today’s youth, amplify the experiences and ideas of young people, and equip attendees with practical tools and innovative approaches to create meaningful change. Each forum will continue the exploration of ways we can reduce disparities in healthcare, demonstrate cultural humility, address, and deconstruct bias, have difficult and productive conversations, learn about valuable resources, increase inclusion, advance equity in healthcare. Please register for this event by visiting this link. * Motivo is an independent company providing a virtual forum on behalf of the health plan. KYBCBS-CDCRCM-029400-23-CPN29379 Effective September 1, 2023, we will upgrade to the 27th edition of MCG Care Guidelines for the following modules: - Inpatient & Surgical Care (ISC)
- General Recovery Care (GRG)
- Recovery Facility Care (RFC)
- Behavioral Health Care (BHG)
- Home Care (HC)
- Ambulatory Care (AC)
The below tables highlight new guidelines and changes. Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive. Goal Length of Stay (GLOS) for Inpatient & Surgical Care (ISC)Guideline | MCG code | 26th edition GLOS | 27th edition GLOS | *Electrophysiologic Study and Implantable Cardioverter-Defibrillator (ICD) Insertion | M-157 | Ambulatory or 1 day postoperative | Ambulatory | *Renal Failure, Acute | M-326 | 3 days | 2 days | *Paraplegia, Acute | M-255 | 8 days | 7 days | *Tetraplegia, Acute | M-305 | 9 days | 7 days | *Percutaneous Revascularization, Lower Extremity | S-1310 | Ambulatory or 1 day postoperative | Ambulatory | *Splenectomy by Laparoscopy | S-1062 | 1 day postoperative | Ambulatory or 1 day postoperative | *Elbow Arthroplasty | S-420 | Ambulatory or 1 day postoperative | Ambulatory | *Elbow Fracture, Open Treatment | S-424 | Ambulatory or 1 day postoperative | Ambulatory | *Foot Fracture, Calcaneus or Talus, Open Reduction, Internal Fixation (ORIF) | S-490 | Ambulatory or 1 day postoperative | Ambulatory | *Foot: Surgical Wound Care | S-495 | Ambulatory or 1 day postoperative | Ambulatory | *Hip Resurfacing | S-565 | 2 days postoperative | Ambulatory or 1 day postoperative | *Knee Dislocation, Closed or Open Reduction | S-675 | Ambulatory or 1 day postoperative | Ambulatory | *Shoulder Arthroplasty | S-634 | 1 day postoperative | Ambulatory or 1 day postoperative | *Appendectomy, without Abscess or Peritonitis, Pediatric | P-25 | Ambulatory or 1 day postoperative | Ambulatory | *Hip: Congenital Dislocation, Open Reduction | P-590 | 1 day postoperative | Ambulatory or 1 day postoperative | *Renal Transplant, Pediatric | P-1015 | 6 days postoperative | 5 days postoperative | *Slipped Upper Femoral Epiphysis, Closed Reduction | P-443 | Ambulatory or 1 day postoperative | Ambulatory | *Tibial Osteotomy, Child or Adolescent | S-1131 | Ambulatory or 1 day postoperative | Ambulatory | *Bladder Incision: Cystotomy | S-200 | Ambulatory or 1 day postoperative | Ambulatory | *Ureterotomy, Nontransurethral for Stone | S-1150 | 1 day postoperative | Ambulatory or 1 day postoperative |
New Guidelines for Inpatient & Surgical Care (ISC)Body system | Guideline title | MCG code | Hospital-at-Home | COVID-19: Hospital-at-Home | M-281-HaH | Hospital-at-Home | Viral Illness, Acute: Hospital-at-Home | M-280-HaH | Observation Care Guidelines | COVID-19: Observation Care | OC-068 | Pediatrics | COVID-19, Pediatric | P-281 | Thoracic Surgery and Pulmonary Disease | COVID-19 | M-281 |
New Guidelines for Recovery Facility Care (RFC)Body system | Guideline title | MCG code | Cardiovascular Surgery | Percutaneous Revascularization, Lower Extremity | S-6310 | Thoracic Surgery and Pulmonary Disease | COVID-19 | M-5281 |
New Guidelines for Home Care (HC)Body system | Guideline title | MCG code | Cardiovascular Surgery | Percutaneous Revascularization, Lower Extremity | S-3310 | Thoracic Surgery and Pulmonary Disease | COVID-19 | M-2281 |
New Guidelines for Ambulatory Care (AC)Body system | Group | Guideline title | MCG code | Genetic Medicine | Oncology | Oncology Companion Diagnostic Testing -FoundationOne CDx | A-1055 | Genetic Medicine | Oncology | Oncology Companion Diagnostic Testing -Guardant360 CDx | A-1056 | Procedures and Diagnostic Tests | Neurology | EEG, Quantitative (Brain Mapping) | A-1050 | Procedures and Diagnostic Tests | Orthopedics | Neurolysis, Genicular Nerve | A-1047 | Procedures and Diagnostic Tests | Orthopedics | Sacroiliac Joint Injection | A-1048 | Procedures and Diagnostic Tests | Thoracic Surgery and Pulmonary Disease | Endobronchial Ultrasound | A-1049 | Specialty Medications | Eye Conditions | Faricimab-svoa | A-1051 | Specialty Medications | Hematologic Conditions | Betibeglogene Autotemcel | A-1057 | Specialty Medications | Oncologic Conditions | Ciltacabtagene Autoleucel | A-1052 | Specialty Medications | Pulmonary Conditions | Tezepelumab-ekko | A-1053 |
If you have questions, please contact the provider service number on the back of the member's ID card. KYBCBS-CD-021785-23-CPN20908 Clinical Criteria updates SummaryOn September 12, 2022, and November 18, 2022, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross and Blue Shield Medicaid (Anthem). These policies were developed, revised, or reviewed to support clinical coding edits. Visit Clinical Criteria to search for specific policies. If you have questions or additional information, use this email. Please see the explanation/definition for each category of Clinical Criteria below: - New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive
Please share this notice with other providers in your practice and office staff. Please note: - The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Document number | Clinical Criteria title | New or revised | September 10, 2023 | *CC-0222 | Tecvayli (teclistamab-cqyv) | New | September 10, 2023 | *CC-0223 | Imjudo (tremelimumab-actl) | New | September 10, 2023 | *CC-0224 | Pedmark (sodium thiosulfate injection) | New | September 10, 2023 | *CC-0225 | Tzield (teplizumab) | New | September 10, 2023 | CC-0130 | Imfinzi (durvalumab) | Revised | September 10, 2023 | *CC-0107 | Bevacizumab for Non-Ophthalmologic Indications | Revised | September 10, 2023 | CC-0148 | Agents for Hemophilia B | Revised | September 10, 2023 | CC-0149 | Select Clotting Agents for Bleeding Disorders | Revised | September 10, 2023 | CC-0065 | Agents for Hemophilia A and von Willebrand Disease | Revised | September 10, 2023 | *CC-0124 | Keytruda (pembrolizumab) | Revised | September 10, 2023 | *CC-0168 | Tecartus (brexucabtagene autoleucel) | Revised | September 10, 2023 | *CC-0195 | Abecma (idecabtagene vicleucel) | Revised | September 10, 2023 | *CC-0150 | Kymriah (tisagenlecleucel) | Revised | September 10, 2023 | *CC-0151 | Yescarta (axicabtagene ciloleucel) | Revised | September 10, 2023 | *CC-0187 | Breyanzi (lisocabtagene maraleucel) | Revised | September 10, 2023 | *CC-0214 | Carvykti (ciltacabtagene autoleucel) | Revised | September 10, 2023 | CC-0133 | Aliqopa (copanlisib) | Revised | September 10, 2023 | *CC-0041 | Complement Inhibitors | Revised | September 10, 2023 | *CC-0071 | Entyvio (vedolizumab) | Revised | September 10, 2023 | *CC-0064 | Interleukin-1 Inhibitors | Revised | September 10, 2023 | *CC-0042 | Monoclonal Antibodies to Interleukin-17 | Revised | September 10, 2023 | *CC-0066 | Monoclonal Antibodies to Interleukin-6 | Revised | September 10, 2023 | *CC-0050 | Monoclonal Antibodies to Interleukin-23 | Revised | September 10, 2023 | *CC-0078 | Orencia (abatacept) | Revised | September 10, 2023 | *CC-0063 | Stelara (ustekinumab) | Revised | September 10, 2023 | *CC-0062 | Tumor Necrosis Factor Antagonists | Revised | September 10, 2023 | *CC-0003 | Immunoglobulins | Revised | September 10, 2023 | CC-0072 | Selective Vascular Endothelial Growth Factor (VEGF) Antagonists | Revised | September 10, 2023 | *CC-0100 | Istodax (romidepsin) | Revised | September 10, 2023 | *CC-0204 | Tivdak (tisotumab vedotin-tftv) | Revised | September 10, 2023 | *CC-0205 | Fyarro (siroliumus albumin bound) | Revised | September 10, 2023 | *CC-0182 | Iron Agents | Revised |
KYBCBS-CD-018991-23-CPN18398 Clinical Criteria updates On August 19, 2022, and March 23, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross and Blue Shield Medicaid (Anthem). These policies were developed, revised, or reviewed to support clinical coding edits. Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email. Please see the explanation/definition for each category of Clinical Criteria below: - New: Newly published criteria
- Revised: Addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.
Please share this notice with other providers in your practice and office staff. Please note:- The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Clinical Criteria number | Clinical Criteria title | New or revised | September 10, 2023 | *CC-0235 | Revcovi (elapegademase-lvlr) | New | September 10, 2023 | *CC-0236 | Signifor LAR (pasireotide) | New | September 10, 2023 | CC-0125 | Opdivo (nivolumab) | Revised | September 10, 2023 | CC-0072 | Vascular Endothelial Growth Factor (VEGF) Inhibitors | Revised | September 10, 2023 | CC-0038 | Human Parathyroid Hormone Agents | Revised | September 10, 2023 | CC-0066 | Monoclonal Antibodies to Interleukin-6 | Revised | September 10, 2023 | *CC-0197 | Jemperli (dostarlimab-gxly) | Revised | September 10, 2023 | *CC-0119 | Yervoy (ipilimumab) | Revised | September 10, 2023 | CC-0092 | Adcetris (brentuximab vedotin) | Revised | September 10, 2023 | *CC-0065 | Hemophilia A and von Willebrand Disease | Revised | September 10, 2023 | *CC-0034 | Agents for Hereditary Angioedema | Revised | September 10, 2023 | CC-0061 | GnRH Analogs for the Treatment of Non-Oncologic Indications | Revised | September 10, 2023 | CC-0008 | Subcutaneous Hormonal Implants | Revised | September 10, 2023 | CC-0026 | Testosterone, Injectable | Revised |
KYBCBS-CD-027396-23-CPN26410 Clinical Criteria Updates On December 22, 2022, May 2, 2023, and May 19, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross and Blue Shield (Anthem). These policies were developed, revised, or reviewed to support clinical coding edits. Visit Clinical Criteria to search for specific policies. If you have questions or need additional information, use this email. Please see the explanation/definition for each category of Clinical Criteria below: - New: Newly published criteria
- Revised: Addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.
Please share this notice with other providers in your practice and office staff. Please note: - The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Clinical Criteria number | Clinical Criteria title | New or revised | September 18, 2023 | *CC-0237 | Qalsody (tofersen) | New | September 18, 2023 | *CC-0238 | Hydroxyprogesterone caproate | New | September 18, 2023 | *CC-0240 | Zynyz (retifanlimab-dlwr) | New | September 18, 2023 | CC-0165 | Trodelvy (sacituzumab govitecan) | Revised | September 18, 2023 | CC-0002 | Colony Stimulating Factor Agents | Revised | September 18, 2023 | CC-0128 | Tecentriq (atezolizumab) | Revised | September 18, 2023 | CC-0098 | Doxorubicin Liposome (Doxil, Lipodox) | Revised | September 18, 2023 | CC-0101 | Torisel (temsirolimus) | Revised | September 18, 2023 | CC-0107 | Bevacizumab for Non-Ophthalmologic Indications | Revised | September 18, 2023 | CC-0143 | Polivy (polatuzumab vedotin-piiq) | Revised | September 18, 2023 | CC-0092 | Adcetris (brentuximab vedotin) | Revised | September 18, 2023 | CC-0095 | Velcade (bortezomib) | Revised | September 18, 2023 | CC-0105 | Vectibix (panitumumab) | Revised | September 18, 2023 | CC-0178 | Synribo (omacetaxine mepesuccinate) | Revised | September 18, 2023 | CC-0114 | Jevtana (cabazitaxel) | Revised | September 18, 2023 | CC-0145 | Libtayo (cemiplimab-rwlc) | Revised | September 18, 2023 | *CC-0032 | Botulinum Toxin | Revised | September 18, 2023 | CC-0068 | Growth Hormone | Revised | September 18, 2023 | *CC-0057 | Krystexxa (pegloticase) | Revised | September 18, 2023 | *CC-0125 | Opdivo (nivolumab) | Revised | September 18, 2023 | *CC-0225 | Tzield (teplizumab-mzwv) | Revised | September 18, 2023 | *CC-0124 | Keytruda (pembrolizumab) | Revised |
MULTI-BCBS-CR-031946-23-CPN30755 The following Anthem Blue Cross and Blue Shield (Anthem) medical policies and clinical guidelines were reviewed on November 10, 2022, for Indiana, Kentucky, Missouri, Ohio, and Wisconsin. To view medical policies and utilization management guidelines, go to anthem.com > Select Providers > Select your state > Under Provider Resources, select Policies, Guidelines & Manuals. To help determine if prior authorization is needed for Anthem members, go to anthem.com > Select Providers > Select your state > Under Claims, select Prior Authorization. You can also call the prior authorization phone number on the back of the member’s ID card. To view medical policies and utilization management guidelines applicable to members enrolled in the Blue Cross and Blue Shield Service Benefit Plan (commonly referred to as the Federal Employee Program® [FEP]), please visit fepblue.org > Policies & Guidelines. Below are the current clinical guidelines and/or medical policies we reviewed and updates that were approved. Policy/Guideline | Information | Effective date | *MED.00013 Parenteral Antibiotics for the Treatment of Lyme Disease | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to one hour — adding policy to Precert. | December 1, 2023 |
* Denotes prior authorization required The following Anthem Blue Cross and Blue Shield (Anthem) Medical Polices and Clinical Utilization Management Guidelines were reviewed on July 31, 2023, for Indiana, Kentucky, Missouri, Ohio, and Wisconsin. To view Medical Policies and Clinical Utilization Management Guidelines, go to anthem.com > select Providers > select your state > under Provider Resources > select Policies, Guidelines & Manuals. To help determine if prior authorization is needed for Anthem members, go to anthem.com > select Providers > select your state > under Claims > select Prior Authorization. You can also call the prior authorization phone number on the back of the member’s ID card. To view Medical Polices and Clinical Utilization Management Guidelines applicable to members enrolled in the Blue Cross and Blue Shield Service Benefit Plan (commonly referred to as the Federal Employee Program® FEP®), please visit fepblue.org > Policies & Guidelines. Below are the new Medical Policies and/or Clinical Utilization Management Guidelines that have been approved. * Denotes prior authorization required. Policy/Guideline | Information | Effective date | *CG-SURG-28 Locoregional Techniques for Treating Primary and Metastatic Liver Malignancies | Add 37243 to PA — Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural road mapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction (when specified as TAE, or TACE not using drug-loaded microspheres or drug-eluting beads or an immunologic agent) | 12/1/2023 | *RAD.00059 Catheter-based Embolization Procedures for Malignant Lesions Outside the Liver | Add 37243 to PA — Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural road mapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction (when specified as TAE, or TACE not using drug-loaded microspheres or drug-eluting beads or an immunologic agent) | 12/1/2023 |
The following Anthem Blue Cross and Blue Shield (Anthem) Medical Polices and Clinical Utilization Management Guidelines were reviewed on May 11, 2023, for Indiana, Kentucky, Missouri, Ohio, and Wisconsin. To view Medical Policies and Clinical Utilization Management Guidelines, go to anthem.com > select Providers > select your state > under Provider Resources > select Policies, Guidelines & Manuals. To help determine if prior authorization is needed for Anthem members, go to anthem.com > select Providers > select your state > under Claims > select Prior Authorization. You can also call the prior authorization phone number on the back of the member’s ID card. To view Medical Polices and Clinical Utilization Management Guidelines applicable to members enrolled in the Blue Cross and Blue Shield Service Benefit Plan (commonly referred to as the Federal Employee Program® FEP®), please visit fepblue.org > Policies & Guidelines. Below are the new Medical Policies and/or Clinical Utilization Management Guidelines that have been approved. * Denotes prior authorization required. Policy/guideline | Information | Effective date | *SURG.00161 Nanoparticle-Mediated Thermal Ablation | - Nanoparticle-mediated thermal ablation is considered INV&NMN for all indications
- Added existing CPT® Category III codes 0738T, 0739T considered INV&NMN; also, nonspecific ICD-10-PCS code 0V503ZZ and NOC codes 55899, 64999 considered INV&NMN when specified as nanoparticle ablation
| 12/1/2023 |
Below are the current Medical Policies and/or Clinical Utilization Management Guidelines we reviewed and updates that were approved. * Denotes prior authorization required. Policy/guideline | Information | Effective date | *CG-MED-41 Moderate to Deep Anesthesia Services for Dental Surgery in the Facility Setting | - Revised formatting and hierarchy of MN statement
- Revised criteria regarding children
- Revised formatting of ASA criteria
- Added some diagnosis codes to two ranges
| 12/1/2023 | *CG-MED-66 Cryopreservation of Oocytes or Ovarian Tissue | - Revised MN criteria for cryopreservation of mature oocytes to include: (1) medical and surgical treatment, gonadotoxic therapy and bilateral oophorectomy as possible causes of anticipated infertility; (2) Criterion which states “individual is a candidate based on ovarian reserve and likelihood for successful oocyte cryopreservation (for example, age 45 years or less)”
- Revised criteria so cryopreservation of ovarian tissue is considered MN when criteria are met
- Revised NMN statement to indicate cryopreservation of ovarian tissue is considered NMN when the criteria above are not met
- CPT codes 89398 (NOC) and non-specific codes 89344, 89354 when specified as cryopreservation of ovarian tissue or related services will be considered MN when criteria are met (were NMN for ovarian tissue)
| 12/1/2023 | *CG-SURG-81 Cochlear Implants and Auditory Brainstem Implants | - Reformatted the MN criteria for cochlear implants
- Revised cochlear implantation criteria to include unilateral sensorineural deafness
- Revised unilateral implantation of a hybrid cochlear implant device criteria related to hearing loss in the contralateral ear
- Added diagnosis codes for single sided deafness, procedure codes will now be reviewed for MN criteria for these diagnoses
| 12/1/2023 | DME.00011 Electrical Stimulation as a Treatment for Pain and Other Conditions: Surface and Percutaneous Devices | - Added existing HCPCS code E0761 for electromagnetic treatment device considered INV&NMN
| 12/1/2023 | *GENE.00010 Panel and other Multi-Gene Testing for Polymorphisms to Determine Drug-Metabolizer Status | - Added new CPT PLA code 0392U effective 07/01/2023 for panel test considered INV&NMN
| 12/1/2023 | *GENE.00052 Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | - Reformatted hierarchy for gene panel testing for inherited diseases, testing for cancer susceptibility, testing for cancer management, and molecular profiling for the evaluation of malignancies
- Revised panel testing criteria to remove 50 gene parameters
- Revised acute myeloid leukemia MN statement to include newly diagnosed or relapsed
- Added circulating tumor DNA to scope of document (moved content from GENE.00049 into this document and added new criteria for prostate cancer and advance non-small cell lung cancer)
- Revised molecular profiling criteria to remove progressed following prior treatment language
- Revised NMN statement for Whole Exome Sequencing to address repeat testing
- Code 81455 for panel over 50 genes to be reviewed for MN criteria (was NMN); added existing code 0022U MN in vitro diagnostic (IVD) criteria.
- Codes added from GENE.00049: 0326U molecular profiling MN criteria; 0239U IVD MN criteria; 0179U, 0242U ctDNA panels MN criteria (were INV&NMN); 0306U; 0307U; 0333U; 0356U; 0368U considered NMN (were INV&NMN);
- Added new 07/01/2023 CPT PLA codes: 0391U molecular profiling MN criteria; 0388U, 0397U ctDNA panels MN criteria; 0400U inherited disease panel considered NMN; 0401U risk panel considered INV&NMN
| 12/1/2023 | *SURG.00121 Transcatheter Heart Valve Procedures | - Revised text and formatting in the MN statement for transcutaneous aortic valve replacement (TAVR)
- Revised MN statement for transcatheter pulmonary valve to remove right ventricular outflow tract (RVOT) conduit diameter criteria and added criteria for native and patched RVOT
- Added a new INV&NMN statement addressing TAVR cerebral protection devices
- Revised the INV&NMN statement regarding valve-in-valve repair to address replacement instead of repair
- CPT code 33370 add-on code for cerebral embolic protection will be considered INV&NMN (was being reviewed for TAVR criteria)
| 12/1/2023 | CG-GENE-13 Genetic Testing for Inherited Diseases | - For Tier 2 code 81404, gene SOD1 was changed to review for MN criteria (was NMN)
| 12/1/2023 | *CG-SURG-83 Bariatric Surgery and Other Treatments for Clinically Severe Obesity | - Added HCPCS codes C9784 for endoscopic sleeve gastroplasty and C9785 for outlet reduction TORE effective 07/01/2023, both considered NMN
| 12/1/2023 | *SURG.00011 Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | - Added HCPCS codes Q4272, Q4273, Q4274, Q4275, Q4276, Q4277, Q4278, Q4280, Q4281, Q4282, Q4283, Q4284 effective 07/01/2023 for products considered INV&NMN
| 12/1/2023 | *SURG.00150 Leadless Pacemaker | - Added new CPT Category III codes 0795T, 0796T, 0797T, 0798T, 0799T, 0800T, 0801T, 0802T, 0803T, 0804T effective 07/01/2023 for dual chamber leadless pacemaker considered INV&NMN; added existing ICD-10-PCS code 02PA3NZ for removal considered INV&NMN
| 12/1/2023 | TRANS.00035 Therapeutic use of Stem Cells, Blood, and Bone Marrow Products | - Revised descriptors for HCPCS codes G0460, G0465
| 6/28/2023 | CG-DME-31 Powered Wheeled Mobility Devices | - Revised hierarchy and formatting in the MN statement addressing power seating systems
- Added new MN and NMN criteria to address power seat elevation systems when individuals meet criteria for (uneven) transfers
| 12/1/2023 | CG-GENE-10 Chromosomal Microarray Analysis (CMA) for Developmental Delay, Autism Spectrum Disorder, Intellectual Disability and Congenital Anomalies | - Removed aCGH and replaced it with CMA in the *notation in the Clinical Indications section
| 6/28/2023 | CG-GENE-16 BRCA Genetic Testing | - Revised Clinical Indications to include homologous recombination deficiency pathways to PARP inhibitor criteria
| 12/1/2023 | CG-MED-59 Upper Gastrointestinal Endoscopy in Adults | - Revised Clinical Indications section to remove references to life-limiting comorbidities
| 6/28/2023 | CG-MED-73 Hyperbaric Oxygen Therapy (Systemic/Topical) | - Added continuation criteria to each section on chronic non-healing wounds in MN statement
- Revised formatting and hierarchy in the Clinical Indications sections
- Removed continuation criteria from the NMN statement
- Added Stroke to NMN statement
| 12/1/2023 | CG-SURG-12 Penile Prosthesis Implantation | - Revised hierarchy and formatting of Clinical Indications section
- Removed intra-urethral medications from the MN criteria
| 6/28/2023 | CG-SURG-82 Bone-Anchored and Bone Conduction Hearing Aids | - Removed code 69799 NOC, no longer applicable
| 6/28/2023 | CG-SURG-95 Sacral Nerve Stimulation and Percutaneous or Implantable Tibial Nerve Stimulation for Urinary and Fecal Incontinence; Urinary Retention Previously titled: Sacral Nerve Stimulation and Percutaneous Tibial Nerve Stimulation for Urinary and Fecal Incontinence, Urinary Retention | - Revised title
- Added MN criteria for temporary SNS for urinary and fecal conditions
- Reformatted MN criteria for permanent SNS for urinary and fecal conditions
- Revised the Clinical Indications section IV for percutaneous or implantable tibial nerve stimulation (PTNS) to include implantable devices
| 12/1/2023 | DME.00011 Electrical Stimulation as a Treatment for Pain and Other Conditions: Surface and Percutaneous Devices | - Added existing HCPCS code E0761 for
electromagnetic treatment device considered INV&NMN | 12/1/2023 | MED.00004 Noninvasive Imaging Technologies for the Evaluation of Skin Lesions Previously Titled: Technologies for the Evaluation of Skin Lesions (including Dermatoscopy, Epiluminescence Microscopy, Video microscopy and Ultrasonography) | - Revised title
- Added additional technologies to INV&NMN section
| 12/1/2023 | *SURG.00121 Transcatheter Heart Valve Procedures | - Revised text and formatting in the MN statement for transcutaneous aortic valve replacement (TAVR)
- Revised MN statement for transcatheter pulmonary valve to remove right ventricular outflow tract (RVOT) conduit diameter criteria and added criteria for native and patched RVOT
- Added a new INV&NMN statement addressing TAVR cerebral protection devices
- Revised the INV&NMN statement regarding valve-in-valve repair to address replacement instead of repair
- CPT code 33370 add-on code for cerebral embolic protection will be considered INV&NMN (was being reviewed for TAVR criteria)
| 12/1/2023 | TRANS.00025 Laboratory Testing as an Aid in the Diagnosis of Heart Transplant Rejection | - Revised MN criteria regarding the time frame for AlloMap testing post HT
- Removed the word, Noninvasive from the INV&NMN statement about AlloSource Heart, AlloSeq cell-free DNA, MMDx Heart and myTAIHeart
| | GENE.00009 Gene Expression Profiling and Genomic Biomarker Tests for Prostate Cancer | - Removed CPT PLA code 0053U
| 6/28/2023 | MED.00135 Gene Therapy for Hemophilia | - Revised MN statement on etranacogene dezaparvovec-drlb
- Added MN statement on valoctocogene roxaparvovec-rvox
- Revised first INV&NMN statement and deleted second INV&NMN statement
- No changes to coding
- Codes that may be used for Roctavian (NOC C9399, J3490, J3590) already listed
| 12/1/2023 |
Our utilization management (UM) decisions are based on the appropriateness of care and service needed, as well as the member’s coverage according to their health plan. We do not reward providers or other individuals for issuing denials of coverage, service, or care. We do not make decisions about hiring, promoting, or terminating these individuals based on the idea or thought that they will deny benefits. In addition, we do not offer financial incentives for UM decision makers to encourage decisions resulting in underutilization. Our Medical Policies and UM criteria are online at https://tinyurl.com/2h2r6esf, or you can request a free copy of our UM criteria from our Medical Management department by calling 855-661-2027. Within seven calendar days of the date of denial, providers can discuss a UM denial decision with a physician reviewer by calling us toll-free at 855-661-2027. We are staffed with clinical professionals who coordinate our members’ care and are available 24/7 to accept precertification requests. Secured voicemail is available during off-business hours. A clinical professional will return your call within the next business day. Our staff will identify themselves by name, title, and being with Anthem Blue Cross and Blue Shield Medicaid when initiating or returning calls regarding UM issues. You can submit precertification requests by: - Calling us at 855-661-2028.
- Faxing to 800-964-3627.
- Submitting online via Availity Essentials* at Availity.com.
Have questions about utilization decisions or the UM process?Call our Clinical team at 855-661-2028, Monday through Friday, from 7 a.m. to 7 p.m. * Availity, LLC is an independent company providing administrative support services on behalf of the health plan. KYBCBS-CD-026724-23 Effective October 1, 2023, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by Anthem Blue Cross and Blue Shield Medicaid for Medicaid members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines (including definitions and specific contract provisions/exclusions), take precedence over these PA rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s): Code | Code description | A0430 | Fixed Wing Air Transport | A0431 | Rotary Wing Air Transport | E0465 | Home ventilator, any type, used with invasive interface, (for example, tracheostomy tube) | E0466 | Home ventilator, any type, used with non-invasive interface, (for example, mask, chest shell) | E0467 | Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components, and supplies for all functions | E2500 | Speech generating device, digitized speech, using pre-recorded messages, 8 min. or less | E2502 | Speech generating device, digitized speech, using pre-recorded messages, 8–20 min. | E2506 | Speech generating device, digitized speech, using pre-recorded messages, over 40 min. | E2508 | Speech generating device, synthesized speech, requiring message formulation by spelling | E2512 | Accessory for speech generating device, mounting system |
To request PA, you may use one of the following methods: - Web: Once logged in to Availity Essentials* at Availity.com
- Fax: 800-964-3627
- Phone: 855-661-2028
Not all PA requirements are listed here. Detailed PA requirements are available to providers at providers.anthem.com/kentucky-provider/communications/news-and-announcements on the Resources tab or, for contracted providers, by accessing Availity.com. Providers may also call Provider Services at 855-661-2028 for assistance with PA requirements. * Availity, LLC is an independent company providing administrative support services on behalf of the health plan. UM AROW 4230
KYBCBS-CD-023884-23-CPN23495 Effective for dates of service on and after December 1, 2023, the following code will require prior authorization through Carelon Medical Benefits Management, Inc.* (formerly AIM Specialty Health®). CPT® code | Description | 0042T | Cerebral Perfusion Analysis Using Computed Tomography with Contrast Administration, Including Post-Processing of Parametric Maps with Determination of Cerebral Blood Flow, Cerebral Blood Volume, and Mean Transit Time |
As a reminder, ordering and servicing providers may submit prior authorization requests to Carelon in one of the following ways: - Access Carelon’s ProviderPortalSM directly at providerportal.com:
- Online access is available 24/7 to process orders in real-time and is the fastest and most convenient way to request authorization.
- Access Carelon via the Availity Essentials* website at availity.com.
Note: This update does not apply to the Federal Employee Program®. If you have any questions related to guidelines, please contact Carelon via email at MedicalBenefitsManagement.guidelines@Carelon.com. Additionally, you may access and download a copy of the current and upcoming guidelines here. * Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. Availity, LLC is an independent company providing administrative support services on behalf of the health plan. MULTI-BCBS-CRCM-025225-23-CPN25171 Effective December 1, 2023, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by Anthem Blue Cross and Blue Shield for Medicare members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions take precedence over these precertification rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s): Code | Code description | 64581 | Incision for implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) | 64628 | Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral | C1764 | Event recorder, cardiac (implantable) | E0466 | Home ventilator, any type, used with non-invasive interface, (for example, mask, chest shell) | E0766 | Electrical stimulation device used for cancer treatment, includes all accessories, any type | L5845 | Knee-Shin Sys Stance Flexion | L5910 | Endo Below Knee Alignable Sy |
Not all PA requirements are listed here. Detailed PA requirements are available to providers on anthem.com/medicareprovider on the Resources tab or for contracted providers by accessing Availity.com.* Providers may also call the number on the back of the member’s ID card for assistance with PA requirements. * Availity, LLC is an independent company providing administrative support services on behalf of the health plan.
UM AROW# 4489 MULTI-BCBS-CR-028201-23-CPN27653 Beginning with dates of service on or after December 1, 2023, Anthem Blue Cross and Blue Shield will expand the current Documentation Standards for Episodes of Care — Professional reimbursement policy to apply to facility providers. This policy outlines how and what elements must be documented for an episode of care. The policy will be retitled Documentation Standards for Episodes of Care — Professional and Facility. For specific policy details, visit the reimbursement policy page at Anthem.com. Effective as of June 14, 2023, Anthem Blue Cross and Blue Shield updated the Documentation and Reporting Guidelines for Evaluation and Management (E/M) Services reimbursement policy to include the 2021 American Medical Association (AMA) CPT® Level of Medical Decision Making (MDM) table to align with the 2021-2023 Centers for Medicare & Medicaid Services (CMS) and AMA-CPT code changes. This table will be listed under the policy section titled Selecting a Level of Medical Decision Making for Coding an E/M Service. When determining the level of E/M service using MDM, this table will be used instead of the 1995/1997 CMS risk tables and the Marshfield Clinic tables. Additional updates to this reimbursement policy are as follows: - Documentation submitted in accordance with this reimbursement policy will remain subject to signature and other requirements as stated in the related Documentation for Episodes of Care reimbursement policy. Therefore, the policy was updated to include the following note: All documents are subject to the Documentation Requirements for Episodes of Care policy.
- The Related Coding section was expanded to include “other” E/M services, as defined in the policy.
For specific policy details, visit the corresponding reimbursement policy page from the list below: Through genuine collaboration, we can simplify access to care and help you deliver high-quality, equitable healthcare. Beginning with dates of service on or after December 1, 2023, Anthem Blue Cross and Blue Shield (Anthem) will update the Place of Service – Facility reimbursement policy to include professional services billed under revenue codes 960-983 expanded to 960-989. According to the policy, Evaluation & Management (E/M) services and other professional services: - Must be billed on a CMS-1500 claim form; and
- Are not reimbursable if billed on a UB-04 claim form (excluding E/M services rendered in an emergency room and billed with emergency room revenue codes).
The policy will be retitled Facility Guidelines for Claims related to Professional Services – Facility. For specific policy details, visit the Kentucky reimbursement policy page at anthem.com.MULTI-BCBS-CM-034779-23-CPN34757 In the July 2023 edition of Provider News, reimbursement policy page we announced multiple updates to the Prolonged Services – Professional reimbursement policy Kentucky effective October 1, 2023. To clarify, the update to “remove language requiring providers to report start and stop times for reimbursement eligibility” was effective as of May 19, 2023. Effective June 14, 2023, Anthem Blue Cross and Blue Shield’s split care surgical modifier language was removed from the Global Surgical Package — Professional reimbursement policy and added to a new standalone reimbursement policy titled Split Care Surgical Modifiers — Professional. This policy allows reimbursement based on a percentage of the fee schedule or contracted/negotiated rate for the surgical procedure. The percentage is determined by the modifier that is appended to the procedure code. The Related Coding section of the policy identifies the applicable modifiers and standard reimbursement percentages. For specific policy details, visit the reimbursement policy page at anthem.com. Policy UpdateRobotic Assisted Surgery(Policy G-10004, effective 01/01/2024) Beginning with dates of service on or after December 1, 2023, Robotic Assisted Surgery reimbursement policy for Anthem Blue Cross and Blue Shield Medicaid will expand to include CPT® codes for computer-assisted surgical systems. This policy does not allow separate reimbursement for technology assisted services detailed in the Related Coding section. These services are considered integral to the primary surgical procedure, are included in the primary surgical procedure, and are not separately reimbursed. The Related Coding section of the policy has been updated to include the following computer assisted surgical musculoskeletal navigation procedures: - 0054T: Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image-guidance based on fluoroscopic images (list separately in addition to code for primary procedure)
- 0055T: Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image-guidance based on CT/MRI images (list separately in addition to code for primary procedure)
The policy has been renamed to Technology Assisted Surgical Procedures which defines both robotic assisted and computer assisted techniques. For additional information, please review the Technology Assisted Surgical Procedures reimbursement policy at https://providers.anthem.com/ky. KYBCBS-CD-023726-23-CPN22827 Your Dual-Eligible Special Needs Plan (DSNP) member’s Individualized Care Plan (ICP/CP) is available on Availity* at www.availity.com. We would like the opportunity to discuss identified problems/needs and collaborate on ways to assist the member in meeting their care plan goals. The member and/or caregiver are central to the process and are also invited to attend the Interdisciplinary Care Team (ICT) meeting. Your participation is important. If you would like to participate in the ICT meeting, call us back as soon as possible at 844-408-6568. When contacting us, include the member’s name, date of birth, and Medicare identification number. The case manager will reach out to set up the meeting. Any care plan changes made from the ICT meeting will be available for you to review on Availity one-to-two working days after the meeting. To access the care plan information, your Availity administrator must register you for access to Member Clinical Reports and complete the registration process using Payer Spaces > Preference Center. Once the registration piece is complete, log in to Availity, select Payer Spaces > Payer Tile > Alerts Hub to access the member’s ICP. We are available Monday through Friday, 8 a.m. to 5 p.m., excluding holidays. * Availity, LLC is an independent company providing administrative support services on behalf of the health plan. MULTI-BCBS-CR-024214-23-CPN23812 Specialty pharmacy updates for Anthem Blue Cross and Blue Shield (Anthem) are listed below. Prior authorization clinical review of non-oncology use of specialty pharmacy drugs is managed by the Anthem's Medical Specialty Drug Review team. Review of specialty pharmacy drugs for oncology use is managed by Carelon Medical Benefits Management, Inc.*, a separate company. Important to note: Currently, your patients may be receiving these medications without prior authorization. As of the effective date below, you may be required to request prior authorization review for your patients’ continued use of these medications. Including the National Drug Code (NDC) code on your claim may help expedite claim processing of drugs billed with a not otherwise classified (NOC) code. Prior authorization updatesEffective for dates of service on and after December 1, 2023, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our prior authorization review process. Access our Clinical Criteria to view the complete information for these site of prior authorization updates. Clinical Criteria | Drug | HCPCS or CPT® code(s) | CC-0241 | Elfabrio (pegunigalsidase alfa-iwxj) | J3490, J3590 | CC-0242* | Epkinly (epcoritamab-bysp) | C9399, J3490, J3590, J9999 | CC-0243 | Vyjuvek (beremagene geperpavec) | J3490, J3590 | CC-0062 | Yuflyma (adalimumab-aaty) | J3490, J3590 |
* Oncology use is managed by Carelon Medical Benefits Management. Note: Prior authorization requests for certain medications may require additional documentation to determine medical necessity. Quantity limit updatesEffective for dates of service on and after December 1, 2023, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our quantity limit review process. Access our Clinical Criteria to view the complete information for these quantity limit updates. Clinical Criteria | Drug | HCPCS or CPT® Code(s) | CC-0241 | Elfabrio (pegunigalsidase alfa-iwxj) | J3490, J3590 | CC-0228 | Leqembi (lecanemab) | J0174 | CC-0243 | Vyjuvek (beremagene geperpavec) | J3490, J3590 | CC-0062 | Yuflyma (adalimumab-aaty) | J3490, J3590 |
* Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. MULTI-BCBS-CM-034766-23-CPN34723 Effective April 5, 2023, Sublocade® can no longer be filled at Accredo Specialty Pharmacy.* Members currently filling through Accredo Specialty Pharmacy will need to switch to CVS Specialty Pharmacy.* A member of the CVS Specialty Pharmacy Care team will be contacting prescribers to obtain a new prescription. Prescribers can contact CVS Specialty Pharmacy at 877-254-0015. * Accredo Specialty Pharmacy is an independent company providing pharmacy services on behalf of the health plan. CVS is an independent company providing pharmacy services on behalf of the health plan. MULTI-BCBS-CM-034784-23-CPN34761 The following Part B medications from the current Clinical Criteria Guidelines are included in our medical step therapy precertification review process. Step therapy review will apply upon precertification initiation, in addition to the current medical necessity review (as is current procedure). Step therapy will not apply for members who are actively receiving medications listed below. There are no clinical changes to Clinical Criteria CC-005, Hyaluronan Injections. Based on feedback, the table listing the preferred and non-preferred products has been updated to present the information in a more useful manner. The updated table identifies preferred alternatives based on injection series. Clinical Criteria Guidelines are publicly available on the provider website. Visit the Clinical Criteria page to search for specific criteria. Clinical UM Guidelines | Preferred drug(s) | Nonpreferred drug(s) | CC-0005 | Single injection: Durolane Three injection series: Euflexxa Gel-Syn Five injection series: Supartz | Single injection: Gel-One Monovisc Synvisc-one Two injection series: Hymovis Three Injection series: Orthovisc Synojoynt Synvisc Triluron Trivisc Five injection series: Genvisc 850 Hyalgan Visco-3 |
MULTI-BCBS-CR-031138-23-CPN30365 **This collateral ran originally in the July 1, 2023, newsletter and was also posted on the provider portal with an October 1, 2023, effective date. The new date of service will begin on November 1, 2023.** Effective for dates of service on and after November 1, 2023, the specialty Medicare Part B drug listed in the table below will be included in our precertification review process. Federal and state law, as well as state contract language and CMS guidelines, including definitions and specific contract provisions/exclusions, take precedence over these precertification rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims. HCPCS or CPT® codes | Medicare Part B drugs | J1931 | Aldurazyme (laronidase) | J0256 | Aralast NP (alpha-1 proteinase inhibitor), Prolastin-C (alpha-1 proteinase inhibitor), Zemaira (alpha-1 proteinase inhibitor) | J1786 | Cerezyme (imiglucerase) | J0584 | Crysvita (burosumab-twza) | J1743 | Elaprase (idursulfase) | J3060 | Elelyso (taliglucerase) | J0180 | Fabrazyme (agalsidase beta) | J0257 | Glassia (alpha-1 proteinase inhibitor) | J0638 | Ilaris (canakinumab) | J0221 | Lumizyme (alglucosidase alfa) | J3397 | Mepsevii (vestronidase alfa) | J1458 | Naglazyme (galsulfase) | J0219 | Nexviazyme (avalglucosidase alfa-ngpt) | J0222 | Onpattro (patisiran) | J1322 | Vimizim (elosulfase alfa) | J3385 | Vpriv (velaglucerase) | J0775 | Xiaflex (collagenase clostridium histolyticum) |
MULTI-BCBS-CR-032240-23-CPN31947 The problemIn 2021, there were 2855 cases of congenital syphilis reported for a rate of 77.9 per 100,000 live births. From 2012 to 2021, the number of cases of congenital syphilis increased 754.8% (334 to 2855 cases), concurrent with a 676.2% increase (2.1 to 16.3 per 100,000 lives) in the rate of primary and secondary syphilis among women aged 15 to 44 years.1 Maternal syphilis is associated with a 21% increased risk for stillbirth, 6% increased risk for preterm delivery, and 9% increased risk for neonatal death.2 Optimal treatment of syphilis during pregnancy is estimated to reduce the risk of congenital syphilis by 98%, stillbirth by 82%, preterm birth by 64%, and neonatal mortality by 80%.3 Syphilis is treatable and curable with penicillin. One in two newborn syphilis cases in the United States occur due to gaps in testing and treatment during prenatal care.3 Congenital syphilis: missed prevention opportunities1
You can make a difference — screen appropriately2 and treat early4!Universal screening: All pregnant women at their first prenatal visit. Treat immediately. High risk screening: Twice in third trimester (28 weeks and at delivery).
Ask, document, rescreen: - History of sex with multiple partners
- Sex in conjunction with drug use or transactional sex
- No prenatal care or late entry
- Methamphetamine or heroin use
- Unstable housing or homelessness
- Incarceration of the woman or her partner
- Prior syphilis diagnosis
High prevalence screening: Twice in third trimester (28 weeks and at delivery) for pregnant women who live in communities with high rates of syphilis. For more information, visit https://gis.cdc.gov/grasp/nchhstpatlas/maps.html. Do you know the law in your state? Check your state health department website for updated recommendations. Do you practice in a high prevalence area? Universal screening in the third trimester and at birth are recommended. 1 Centers for Disease Control and Prevention. 2021.Sexually Transmitted Disease Surveillance, 2021 (cdc.gov) cdc.gov/std/statistics/2021/default.htm. 2 Adhikari, Emily H. MD. Syphilis in Pregnancy. Obstetrics & Gynecology 135(5): p1121-1135, May 2020.
3 U.S. Department of Health and Human Services. 2020. Sexually Transmitted Infections National Strategic Plan for the United States: 2021–2025. Washington, DC.
4 Centers for Disease Control and Prevention. 2021.Syphilis - STI Treatment Guidelines (cdc.gov) cdc.gov/std/treatmentguidelines/syphilis.htm. KYBCBS-CDCM-025840-23-CPN25643 Anthem Blue Cross and Blue Shield reimburses providers for Medicare Advantage medication reconciliation. Please see the FAQ to learn how to receive reimbursement for post inpatient discharge medication reconciliation. In line with our commitment to participating practitioners and members, Anthem Blue Cross and Blue Shield Medicaid has a Members’ Rights and Responsibilities section located within the provider manual. The delivery of quality healthcare requires cooperation between patients, their providers, and their healthcare benefit plans. One of the first steps is for patients and providers to understand their rights and responsibilities. Review this section in your provider manual here: https://tinyurl.com/5cm4n4x6 Managing illness can be a daunting task for our members. It is not always easy to understand test results, how to obtain essential resources for treatment, or know who to contact with questions and concerns. Anthem Blue Cross and Blue Shield Medicaid is available to offer assistance in these difficult moments with our Complex Case Management program. Our case managers are part of an interdisciplinary team of clinicians and other resource professionals working to support members, families, PCPs, and caregivers. In addition, the complex case management process uses the experience and expertise of the Case Management team to educate and empower our members by increasing self-management skills. Our complex case managers can help to find services and resources to assist eligible members with chronic conditions that may involve social drivers of health. Our case managers direct members to community resources and make referrals when possible. The complex case management process can help members understand their illnesses and learn about care choices to ensure they have access to quality, efficient healthcare. Members can refer themselves or caregivers and family members can refer members by calling the Member Services number located on the back of their ID card. They will be transferred to a team member based on the immediate need. For example, a member newly diagnosed with diabetes will receive assistance from our diabetic complex case manager, who will help them find diabetic resources available in their community. Providers can refer their patients by contacting us telephonically or through electronic means. We can help with transitions across levels of care so that patients and caregivers are better prepared and informed about healthcare decisions and goals. You can contact us by email at kentuckycm@anthem.com or by phone at 855-661-2027, providers option 2, and case management option 3. Case Management business hours are Monday through Friday from 8 a.m. to 5 p.m. ET, except on holidays. |